Transcriptomic profile of intrinsically chemoresistant acute myeloid leukemia patients

We recently identified three sub-populations of refractory acute myeloid leukemia (AML) patients with distinct intrinsic resistance mechanisms. Furthermore, we were able to risk-stratify the overall survival of the patients and identify patients who would likely benefit from alternative therapies.

Detalles Bibliográficos
Autor principal: Horibata, Sachi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816412/
https://www.ncbi.nlm.nih.gov/pubmed/31692823
http://dx.doi.org/10.1080/23723556.2019.1650631
Descripción
Sumario:We recently identified three sub-populations of refractory acute myeloid leukemia (AML) patients with distinct intrinsic resistance mechanisms. Furthermore, we were able to risk-stratify the overall survival of the patients and identify patients who would likely benefit from alternative therapies.

Ejemplares similares